Developer of cancer therapeutics designed to treat cancer. InxMed is based in Nanjing, China. Its last reported valuation was $306 million in Aug 2025. It has raised $132 million.
Last reported valuation
$306.0M
Oct 2026
Priced at
—
Total raised
$131.6M
Last round
—
Cap table — not yet on record
InxMed's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of InxMed with a free account
·The complete investor list: 11 names
·Watch InxMed: the Monday email on marks, rounds and moves
